- $154.93bn
- $214.40bn
- $58.50bn
- 67
- 63
- 62
- 69
Pfizer Inc - New Data Show Pfizers Axitinib Prolonged Overall Survival in Advan
AnnouncementPfizer Inc - Bextra Status
AnnouncementPfizer Inc - Pfizer Reports Shares of Encysive Pharmaceuticals Inc. Tendered Pur
AnnouncementPfizer Inc - Overweight Dogs in Europe to Benefit from Pfizer U.S. Experience
AnnouncementPfizer Inc Re Contract
AnnouncementPfizer Inc - Regulatory Approval
AnnouncementPfizer Inc - Pfizers Celsentri(R) Approved in the European Union, Providing a N
AnnouncementPfizer Inc - Patients Who Took Investigational Melanoma Compound CP-675,206 Show
AnnouncementPfizer Inc - Single-Agent SUTENT Prolonged Progression-Free Survival across All
AnnouncementPfizer Inc - New Data Evaluating SUTENT, CP-751,871 and Axitinib in Patients wit
AnnouncementPfizer Inc Lyrica Significantly Reduced Pain and Improved Other Symptoms of Post
AnnouncementPfizer Inc - Patients Treated with Lipitor Were Significantly Less Likely to Hav
AnnouncementPfizer Inc - Court Rules for Pfizer in Patent Infringement Case on Neurontin
AnnouncementPfizer Inc - Pfizer Receives Initial Communication from U.S. Patent and Trademar
AnnouncementPfizer Inc - Research Update
AnnouncementRule 2.10 Announcement
AnnouncementPfizer Inc - Pfizer Invites Public to View and Listen to Webcast of July 23 Conf
AnnouncementPfizer Inc Pfizer Discontinues Phase 3 Trial of Sutent® in Metastatic Color
AnnouncementPfizer Inc - Statement re (Exubera Trial)
Announcement